Evidence map›Paper›PMID 24160695›Full record

ReviewAnnual review of pharmacology and toxicology2014

Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery.

Matthew Palombo, Manjeet Deshmukh, Daniel Myers, Jieming Gao, Zoltan Szekely, Patrick J Sinko

Abstract readReview
In one paragraph

Review in Annual review of pharmacology and toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Reflections and Outlook on Multifaceted Biomedical Applications of Graphene.Advances in experimental medicine and biology · 2022
    Article
  10. Article
  11. Current Status of Alginate in Drug Delivery.Advances in pharmacological and pharmaceutical sciences · 2020
    Review
  12. Article
  13. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  14. Lipid core nanoparticles resembling low-density lipoprotein and regression of atherosclerotic lesions: effects of particle size.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018
    Article
  15. Review
  16. Article
  17. Article
  18. Metal Nanomaterial Toxicity Variations Within the Vascular System.Current environmental health reports · 2016
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew PalomboSchool of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854; email: sinko@rci.rutgers.edu.
Manjeet Deshmukh
Daniel Myers
Jieming Gao
Zoltan Szekely
Patrick J Sinko

Funding

UMDNJ/Rutgers University CounterACT Research Center of ExcellenceU54AR055073 · NIAMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI HECK, DIANE E · 2006 to 2024
$71.4M
UMDNJ TRAINING GRANT IN BIOTECHNOLOGYT32GM008339 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1989 to 2019
$6.1M
Enhancing Intestinal & Brain Uptake of Anti-AIDS DrugsR37AI051214 · NIAID · RUTGERS, THE STATE UNIV OF N.J. · PI SINKO, PATRICK J. · 2006 to 2015
$4.4M
Multifunctional PEG Hydrogel Nano/Microparticles for Targeted Treatment of NSCLCR01CA155061 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI SINKO, PATRICK J. · 2011 to 2015
$1.8M
Multiplex Nanocarrier-based Hydrogels for Prevention of Vaginal HIV Transmission.R01AI084137 · NIAID · RUTGERS, THE STATE UNIV OF N.J. · PI SINKO, PATRICK J. · 2009 to 2012
$1.5M
Enhancing Intestinal &Brain Uptake of Anti-AIDS Drugs.R01AI051214 · NIAID · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI SINKO, PATRICK J. · 2002 to 2005
$1.1M
NCI NIH HHS CA155061NCI NIH HHS R01 CA155061NIAID NIH HHS AI051214NIAID NIH HHS AI084137NIAID NIH HHS R01 AI051214NIAID NIH HHS R01 AI084137NIAID NIH HHS R37 AI051214NIAMS NIH HHS U54 AR055073NIAMS NIH HHS U54AR055073NIGMS NIH HHS T32 GM008339
6 · The paper itself

Abstract

Novel engineered nanomaterials (ENMs) are being developed to enhance therapy. The physicochemical properties of ENMs can be manipulated to control/direct biodistribution and target delivery, but these alterations also have implications for toxicity. It is well known that size plays a significant role in determining ENM effects since simply nanosizing a safe bulk material can render it toxic. However, charge, shape, rigidity, and surface modifications also have a significant influence on the biodistribution and toxicity of nanoscale drug delivery systems (NDDSs). In this review, NDDSs are considered in terms of platform technologies, materials, and physical properties that impart their pharmaceutical and toxicological effects. Moving forward, the development of safe and effective nanomedicines requires standardized protocols for determining the physical characteristics of ENMs as well as assessing their potential long-term toxicity. When such protocols are established, the remarkable promise of nanomedicine to improve the diagnosis and treatment of human disease can be fulfilled.

Indexed as

AnimalsChemical PhenomenaDisease Models, AnimalDrug Delivery SystemsDrug Evaluation, PreclinicalHumansNanomedicineNanostructuresParticle SizeTissue Distribution

Identifiers

PMID24160695
PMCPMC4207123

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.